In this study, we utilized SEREX technology to examine the presence of CNN2 antibodies in the serum of individuals with HCC, gastric cancer, lung cancer, colorectal cancer, hepatitis, cirrhosis, and healthy individuals. This evidence concerns the gene CNN2 and hepatocellular carcinoma.